- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06328088
Vegetarian Versus Non Vegetarian Based Diet in the Recurrence of Hepatic Encephalopathy in Patients With Cirrhosis: An Open Label Pilot Study
Effect of Vegetarian Versus Non Vegetarian Based Diet in the Recurrence of Hepatic Encephalopathy in Patients With Cirrhosis:An Open Label Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hepatic encephalopathy (HE) is a neurological complication in cirrhosis and affects 30-80% of these patients. Patient conscious level varies from minimal altered sensorium to deep coma and hence it is classified into two categories, covert HE and overt HE. Its occurrence in patients with cirrhosis merits liver transplantation and it reduces survival rate to 50% in next 1-2 year. HE significantly affects quality of life, inability to drive, morbidity and mortality . Recovery from single episode of HE merits secondary prophylaxis with lactulose and rifaximin .
Protein calorie malnutrition is also common in patients with cirrhosis and its prevalence varies from 30-90% depending upon the method of evaluation and types of patients enrolled . Sarcopenia negatively affects survival and can be precipitated by repeated episodes of admission and HE in patients with cirrhosis. Earlier protein restriction was advocated in the treatment of HE but later this concept was refuted and increase protein intake was advocated in patients with HE . Diet in patients during an episode HE is also not known. It is advisable based on many case reports or case series that vegetable-based diet during the episode of HE is better than animal-based diet as it reduces ammonia level and other false neurotransmitters in brain and helps in early recovery of, HE . However, diet in patients who had recovered from an episode of, HE is not known and what type of protein (vegetarian or non-vegetarian) should be taken to prevent another episode of HE has never been evaluated. In India majority of the patients are vegetarian and patients with cirrhosis are malnourished and lack protein in their diet as per our previous published study . We wish to study effect of diet on the recurrence of HE in patient with cirrhosis who had recovered completely from an episode of HE and are on secondary prophylaxis of HE.
Materials and methods:
Consecutive patients with cirrhosis who have recovered from an episode of HE will be screened and enrolled in the study if fulfilling the enrolment criteria. Cirrhosis will be diagnosed based on clinical, radiological, Transient elastography and biopsy if available. All relevant investigation will be done to evaluate the cause of cirrhosis (Viral markers, autoimmune markers etc). HE will be diagnosed based on West Heaven criteria and recovery will be assessed by the senior Consultant of this study. All patient will undergo handgrip strength test to assess muscle strength, number connection test and critical flicker frequency test to assess minimal hepatic encephalopathy at baseline and at 1,3 and 6 month interval.
Handgrip test: This is a simple bed side test non-invasive tests in which patient will sit on a chair and held a instrument and press it as hard as possible after a training session to get the muscle strength. Its value will be recorded (26).
Number connection test: It is simple bed side paper and pencil tests.In a paper numbers are written from 1 to 25 in a random session and patient will join the number as fast as possible and result will be recorded(4) Critical flicker frequency tests: It is again a simple bed side test in which patient will see an instrument and a light source. Patient will see the flickering of light and he will record it by pushing a button. Its value will be recorded(27).
Blood tests which includes complete blood count,liver and kidney function tests,INR will be assessed at baseline,1,3 and 6 month as per standard practise in these patients.
Assessment of dietary intake All patients will be assessed by investigator and trained dietician for the calculation of total calories, carbohydrates, protein and fat by 24 recall method. Assessment of these parameters will be compared as per standard recommendation by INASL guidelines(10). If patient is taking less calories or proteins, these will be supplemented according to patient choice of food and as per standard guidelines.
Vegetarian subjects: Protein will be supplemented as per recommendation 1.5 gm/kg body weight and it will be supplemented with vegetable source. Milk and milk products are allowed in this group as most of the Indians who are vegetarian also consume milk and milk products. Egg and meat products are not allowed.
Non vegetarian subjects: Protein will be supplemented by both vegetarian and non-vegetarian diet. Patients will be encouraged to take more>50% of total daily protein requirement as non-vegetarian based protein which will include eggs and meat products. Due to cultural belief in India people do not take non vegetarian food on daily basis. Patients will maintain a dairy of their daily protein source. If patient is taking less than 50% of his daily protein from non-vegetarian source for more than 10 days per month these patients will be taken as non-compliant and will be recorded.
Randomisation protocol: This will be an open label study and patients will be divided into two groups based on their dietary pattern previous to enrolling in this study. Patients who are strict vegetarian will be grouped into vegetarian group and patients who are non vegetarian will be given a choice to enrol in any group and will be randomised accordingly.
Follow up protocol:
All patients will be followed by the investigator at baseline, fifteen days and then at one month interval for 6 months from day of enrolment in the study. All patients are free to come to hospital at any time in case of any medical issue and will be assessed as per standard protocol. All patients will be managed as per standard practise and all previous medications like beta blockers, diuretics, antiviral therapy, lactulose and rifaximin will be continued if taking. Patient on secondary prophylaxis for HE with lactulose with or without rifaximin will continue the medications.
Management of Hepatic encephalopathy: All patients will be managed as per standard protocol with correction of precipitating factors, lactulose, L ornithine L aspartate infusion or sachets and rifaximin. Patients with more than grade 2 encephalopathy will be admitted
Statistical methods:
The results of this study will be expressed as mean± standard error. The p value of < 0.05 will be considered statistically significant. Data will be compared using the non-parametric Mann-Whitney test for continuous data and Fisher test for categorical data. Comparisons of the variables will be performed using the Wilcoxon test and Fisher test as needed. Statistical analyses of the data will be performed by using SPSS 23 Statistical Software (SPSS Inc. and Microsoft Corp., Chicago, IL).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Praveen Sharma, MD,DM
- Phone Number: 9810365151
- Email: drpraveen_sharma@yahoo.com
Study Locations
-
-
-
Delhi, India, 110060
- Recruiting
- Sir Ganga Ram Hospital
-
Contact:
- Praveen Sharma, MD,DM
- Phone Number: 9810365151
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- 1) Age 18 years and older. 2) Confirmed diagnosis of liver cirrhosis. (Diagnosed on the basis of clinical, biochemical, radiological or endoscopic features).
3) Willingness to sign informed consent proforma. 4) Patients who recovered from Hepatic encephalopathy will be enrolled from Out patient Department within 15 days of discharge
Exclusion Criteria:
- 1) Patients with underlying severe cardiopulmonary disease or hepatocellular carcinoma.
2) Patients with CTP score of more than 12 3) Patient not willing for follow up or consent to participate in the study
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Non vegetarian diet
|
Non vegetarian diet plus supportive treatment including lactulose and/or rifaximin
|
|
Vegetarian diet
|
Non vegetarian diet plus supportive treatment including lactulose and/or rifaximin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Recurrence of overt hepatic encephalopathy
Time Frame: 6 month follow up
|
6 month follow up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Hospitalization due to any cause
Time Frame: six month
|
six month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EC/12/23/2400
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Encephalopathy
-
Jinnah Postgraduate Medical CentreNot yet recruitingHepatic Encephalopathy Stage 2 | Hepatic Encephalopathy Stage 3 | Hepatic Encephalopathy Stage 4Pakistan
-
Sohag UniversityNot yet recruiting
-
Qin NingCompletedHepatic Encephalopathy | Minimal Hepatic Encephalopathy | Overt Hepatic EncephalopathyChina
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterInstituto Grifols, S.A.; McGuire Research InstituteCompletedHepatic Encephalopathy | Cirrhosis | Minimal Hepatic Encephalopathy | Covert Hepatic EncephalopathyUnited States
-
Sherief Abd-ElsalamTanta UniversityUnknownEncephalopathy, HepaticEgypt
-
Institute of Liver and Biliary Sciences, IndiaWithdrawnRefractory Hepatic EncephalopathyIndia
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Aga Khan UniversityUnknownEncephalopathy, Hepatic | Hepatocerebral Encephalopathy | Portal-Systemic Encephalopathy | Encephalopathy, HepatocerebralPakistan
-
Shanghai Changzheng HospitalEnrolling by invitationHepatic Encephalopathy | Covert Hepatic EncephalopathyChina
-
Bausch Health Americas, Inc.CompletedOvert Hepatic EncephalopathyUnited States
Clinical Trials on Non vegetarian
-
Region SkaneRecruitingHealthy Volunteers | Inflammatory Bowel Disease (IBD)Sweden
-
Radboud University Medical CenterRecruitingMyocardial InfarctionNetherlands
-
Göteborg UniversityNot yet recruiting
-
Edith Cowan UniversityRoyal Perth Hospital; Fiona Stanley Fremantle Hospitals Group; St John of God...CompletedInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisAustralia
-
Azienda Ospedaliero-Universitaria CareggiCompleted
-
University of TorontoCanadian Institutes of Health Research (CIHR)UnknownCardiovascular Diseases | Stroke | Mortality | Coronary Heart DiseaseCanada
-
University of TorontoCanadian Institutes of Health Research (CIHR); Canadian Diabetes Association; The Physicians' Services Incorporated Foundation and other collaboratorsUnknown
-
Purdue UniversityCompletedDiet ModificationUnited States
-
Mahidol UniversityCompletedInflammatory Bowel Diseases | Fecal Microbiota | Calprotectin | Vegetarian DietThailand